Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1005764

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NHS and medical professional body guidelines on the prescription of medicinal cannabis in ensuring the eligibility for prescription of patients for whom that treatment might be advantageous.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	190361
answer	answer is ministerial correction date of answer 15/11/2018 answer text <p>The Medical Director of NHS England, Professor Steve Powis, and the Chief Medical Officer, Professor Dame Sally Davies, have written to relevant clinicians to coincide with the coming into force of the rescheduling of cannabis-based medicinal products. The guidance in this letter, which signposts interim clinical advice commissioned from the British Paediatric Neurology Association and the Royal College of Physicians, is in line with normal clinical practice. The decision to prescribe cannabis-based products for medicinal use will be made on a case-by-case basis, based on clinical need and in-line with existing governance procedures for prescribing unlicensed medicines.</p><p> </p><p>The Department has commissioned the National Institute for Health and Care Excellence to produce clinical guidance by October 2019, which will update and replace the interim advice.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/11/2018 12:47:21 answering member 4067 label Biography information for Steve Brine
tabling member	478 label Biography information for Lord Field of Birkenhead

1002678

registered interest
date	06/11/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, if he will publish the advice used to inform his Department on the requirements that (a) the decision to prescribe medicinal cannabis products must be made by a specialist doctor and (b) medicinal cannabis products may only be prescribed when the patient has an unmet special clinical need that cannot be met by other treatments.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	188750
answer	answer is ministerial correction date of answer 12/11/2018 answer text <p>The prescription of these products by doctors on the Specialist Register of the General Medical Council (GMC) and only where there is an unmet clinical need follows the principles used by the Interim Expert Panel on cannabis-based products for medicinal use. This approach was agreed by senior clinicians on the Expert Panel, Chaired by Dr Michael McBride, Chief Medical Officer for Northern Ireland. This approach was subsequently supported by the Advisory Council on the Misuse of Drugs (ACMD) in their advice to the Home Secretary on rescheduling cannabis. The ACMD advice has been published and is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products" target="_blank">https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products</a></p><p>Any unlicensed medicines, including cannabis-based products for medicinal use, will be supplied under long-standing arrangements for the supply of what are known, in healthcare settings, as ‘specials’. This process is underpinned by the Human Medicines Act and, outside of clinical trials, only allows these unlicensed medicines to be prescribed where there is an unmet clinical need. This restriction is in place because unlicensed medicines have not been through the same quality, safety and efficacy tests as licenced medicines.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 12/11/2018 17:05:51 answering member 1561 label Biography information for Mr Nick Hurd
tabling member	1439 label Biography information for Norman Lamb

1002107

registered interest
date	05/11/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, whether his Department remains the ministerial lead for the medicinal use of cannabis-based products.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	188186
answer	answer is ministerial correction date of answer 15/11/2018 answer text <p>The Home Office leads the Government’s policy and legislation on the misuse of drugs, including on the scheduling of substances controlled under the Misuse of Drugs Act 1971 and associated legislation. The Department of Health and Social Care has responsibility for the safe management and use of medicines in healthcare.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 15/11/2018 17:58:05 answering member 1561 label Biography information for Mr Nick Hurd
tabling member	4465 label Biography information for Ronnie Cowan

990352

registered interest
date	18/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to allow patients to have access to NHS doctors willing to prescribe cannabis-based medicine in cases where their NHS doctor is unwilling to do so.
tabling member constituency	Cardiff West
tabling member printed	Kevin Brennan
uin	181179
answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>NHS England expects that cannabis-based products for medicinal use should only be prescribed for indications where there is clear evidence of benefit, and in patients where there is a clinical need which cannot be met by a licensed medicine and, where established treatment options have been exhausted.</p><p> </p><p>The decision to prescribe these unlicensed medicines must be made by a specialist doctor – not a general practitioner. These doctors focus on one field of medicine such as neurology or paediatrics and are listed on the General Medical Council’s specialist register. They must make decisions on prescribing cannabis-based products for medicinal use on a case by case basis, and only when the patient has an unmet special clinical need that cannot be met by licensed products. In addition, a specialist on the General Medical Council Register should only prescribe within their own area of practice, and the decision to prescribe should be agreed by the multidisciplinary team.</p><p> </p><p>NHS England, the British Paediatric Neurology Association and the Royal College of Physicians will provide clinical advice to doctors ahead of the law change. The National Institute for Health and Care Excellence has been commissioned to develop more detailed guidelines for clinicians in the longer term.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:43:24 answering member 4067 label Biography information for Steve Brine
tabling member	1400 label Biography information for Kevin Brennan

988887

registered interest
date	16/10/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, whether GPs will be required to notify (a) the police and (b) the Home Office when making prescriptions for medicinal cannabis.
tabling member constituency	Lewisham, Deptford
tabling member printed	Vicky Foxcroft
uin	180264
answer	answer is ministerial correction date of answer 24/10/2018 answer text <p>From 1 November, certain cannabis-based products for medicinal use, that meet conditions related to the quality of their manufacture and supply routes, can be prescribed by doctors on the specialist register of the General Medical Council (GMC). GPs will not be able to prescribe cannabis-based medicinal products for their patients.</p><p>There is no requirement for specialist doctors to notify the police or the Home Office when issuing prescription for these products. Controlled Drug Accountable Officers have a statutory responsibility to secure the safe management and use of controlled drugs. This includes a duty to monitor the prescribing, supply and administration (if applicable) of all controlled drugs and liaise with the police to investigate suspected diversion.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 24/10/2018 15:40:57 answering member 1561 label Biography information for Mr Nick Hurd
tabling member	4491 label Biography information for Vicky Foxcroft

988889

registered interest
date	16/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether all patients with health conditions previously determined by the Medicines and Healthcare products Regulatory Agency to benefit from the use of cannabis will automatically qualify for prescriptions for medicinal cannabis.
tabling member constituency	Lewisham, Deptford
tabling member printed	Vicky Foxcroft
uin	180265
answer	answer is ministerial correction date of answer 24/10/2018 answer text <p>Subject to Parliamentary approval, from 1 November doctors on the General Medical Council’s specialist register can make the decision to prescribe cannabis-based products for medicinal use where deemed clinically appropriate and in the best interests of patients. Prescribers will need to follow local governance procedures for prescribing unlicensed medicines.</p><p> </p><p>The regulations do not limit the types of conditions that can be considered for treatment and will only be able to be supplied under the prescription or direction of a specialist doctor.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/10/2018 16:57:55 answering member 4067 label Biography information for Steve Brine
tabling member	4491 label Biography information for Vicky Foxcroft

972291

registered interest
date	12/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Home Secretary on the potential effect of legalising cannabis-oil medicines on the availability of cannabis as a gateway drug for social use.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	173953
answer	answer is ministerial correction date of answer 09/10/2018 answer text <p>The Secretary of State for Health and Social Care has committed to his officials working closely with the Home Office on legalising the use of cannabis-based medicines, including cannabis-oil. There has not been a meeting between the Secretary of State and the Home Secretary on the potential effect of legalising cannabis-oil medicines on the availability of cannabis as a gateway drug for social use.</p><p> </p><p>An impact assessment is being prepared alongside proposals to consider wider impacts of this policy. There are known harms associated with cannabis use and cannabis remains a controlled drug. The Government has no plans to legalise it for recreational use. As with other medicines in Schedule 2 to the Misuse of Drugs Regulations 2001 (such as morphine and fentanyl), it will continue to be an offence contrary to the Misuse of Drugs Act 1971 to possess a cannabis based medicine without prescription or lawful authority.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/10/2018 16:51:24 answering member 4067 label Biography information for Steve Brine
tabling member	308 label Biography information for Mr Jim Cunningham

971604

registered interest
date	11/09/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, what assessment he has made of whether there is a correlation between the unrestricted sale of natural cannabis oil in health stores and the number of thefts on the high street; and if he will make a statement.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	173514
answer	answer is ministerial correction date of answer 09/10/2018 answer text <p>We do not hold data to assess whether there is a correlation between the sale of natural cannabis oil and the number of thefts on the high street.</p><p>A CBD, or cannabidiol product, in its pure form is not controlled under the Misuse of Drugs Act 1971. However, a CBD product, which contains any trace of the psychoactive compounds that are found in cannabis, such as THC, is considered to be a controlled substance under the Misuse of Drugs Act 1971 and therefore unlawful to possess and supply unless it fits the criteria for an ‘exempt product’ under the Misuse of Drugs Regulations 2001.</p><p>Enforcement of illegal sales of drugs is an operational matter for the police but we expect them to enforce the law.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 09/10/2018 15:30:25 answering member 1561 label Biography information for Mr Nick Hurd
tabling member	308 label Biography information for Mr Jim Cunningham

968170

registered interest
date	05/09/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, how many licence applications for medicinal cannabis have been received by the expert panel; and what the status is of those applications.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	170718
answer	answer is ministerial correction date of answer 10/09/2018 answer text <p>Government has announced an aim to reschedule cannabis in the autumn. This will enable specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need. In the interim the Expert Panel has been established to review applications from specialist clinicians who wish to prescribe specified cannabis derived medicinal products. For each application, the panel are looking for a specialist clinician to meet their criteria and show that there are exceptional clinical circumstances before recommending that a licence should be issued.</p><p>As of 06 September 2018 there have been forty four inquiries to the expert panel mailbox from members of the public, patients, doctors and press. The number of applications to the panel has been small there is a significant risk that even aggregate information disclosed about applications could be linked to personal details (made available through media reporting). Given that the Home Office has a duty to protect these individuals the actual number of applications cannot be disclosed.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd grouped question UIN 170719 question first answered 10/09/2018 16:02:09 answering member 1561 label Biography information for Mr Nick Hurd
tabling member	1439 label Biography information for Norman Lamb

968171

registered interest
date	05/09/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, how many inquiries the medicinal cannabis licensing panel has received from potential applicants.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	170719
answer	answer is ministerial correction date of answer 10/09/2018 answer text <p>Government has announced an aim to reschedule cannabis in the autumn. This will enable specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need. In the interim the Expert Panel has been established to review applications from specialist clinicians who wish to prescribe specified cannabis derived medicinal products. For each application, the panel are looking for a specialist clinician to meet their criteria and show that there are exceptional clinical circumstances before recommending that a licence should be issued.</p><p>As of 06 September 2018 there have been forty four inquiries to the expert panel mailbox from members of the public, patients, doctors and press. The number of applications to the panel has been small there is a significant risk that even aggregate information disclosed about applications could be linked to personal details (made available through media reporting). Given that the Home Office has a duty to protect these individuals the actual number of applications cannot be disclosed.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd grouped question UIN 170718 question first answered 10/09/2018 16:02:09 answering member 1561 label Biography information for Mr Nick Hurd
tabling member	1439 label Biography information for Norman Lamb